Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
最近の投稿
- 1
Dolly Parton misses Dollywood event due to 'a few health challenges' after skipping honorary Oscars - 23 Must-Change Settings for iPhone Clients: Safeguard Yourself !
- 3Famous SUVs With Low Energy Utilization In 2024
- 4Figure out how to Keep up with Your Dental Inserts for Long haul Achievement
- 5CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year
- The largest sun of 2026 rises today as Earth draws closest to our parent star
- Some super-smart dogs can pick up new words just by eavesdropping
- Vote In favor of Your Favored Distributed computing Administration
- Hilary Duff announces new album ‘Luck… or Something,’ her first in over 10 years: ‘Excited is the largest understatement’
- Figure out how to Team up with Your Auto Crash Legal advisor for Best Outcomes
- NASA astronauts take new moonsuit for a swim | Space photo of the day for Nov. 28, 2025
- Brazil approves law strengthening protective measures for female victims of gender-based violence
- Vote In favor of Your Favored Kind Of Vegetable
- Examination In progress into Abuse of Japanese Government-Supported Advance
